What is Zacks Research's Estimate for ALLO Q2 Earnings?

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Allogene Therapeutics in a note issued to investors on Tuesday, June 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($0.27) for the quarter, up from their prior estimate of ($0.32). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.01) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.09) EPS and Q1 2027 earnings at ($0.33) EPS.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.28).

Several other research analysts also recently commented on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $14.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. Citigroup dropped their price objective on Allogene Therapeutics from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. Truist Financial dropped their price objective on Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. HC Wainwright dropped their price objective on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, March 19th. Finally, Robert W. Baird dropped their price objective on Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Allogene Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $8.44.

Allogene Therapeutics Trading Up 10.1%

Allogene Therapeutics stock traded up $0.13 during trading hours on Friday, reaching $1.42. 3,475,725 shares of the company were exchanged, compared to its average volume of 3,318,230. The firm has a market cap of $310.60 million, a price-to-earnings ratio of -0.91 and a beta of 0.60. The stock has a 50-day moving average of $1.34 and a 200 day moving average of $1.76. Allogene Therapeutics has a 12 month low of $0.86 and a 12 month high of $3.78.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Lynx1 Capital Management LP increased its holdings in shares of Allogene Therapeutics by 75.3% during the 4th quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company's stock worth $23,163,000 after purchasing an additional 4,672,349 shares during the period. Goldman Sachs Group Inc. increased its stake in Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company's stock valued at $8,547,000 after acquiring an additional 3,747,397 shares during the period. Frazier Life Sciences Management L.P. increased its stake in Allogene Therapeutics by 34.9% in the first quarter. Frazier Life Sciences Management L.P. now owns 3,868,750 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,001,000 shares during the period. Dimensional Fund Advisors LP increased its stake in Allogene Therapeutics by 30.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company's stock valued at $7,586,000 after acquiring an additional 831,146 shares during the period. Finally, Foresite Capital Management VI LLC bought a new stake in Allogene Therapeutics in the fourth quarter valued at about $7,345,000. Institutional investors own 83.63% of the company's stock.

Insider Transactions at Allogene Therapeutics

In other news, CEO David D. Chang sold 46,668 shares of the business's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 61,757 shares of company stock worth $115,873. 13.20% of the stock is currently owned by company insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).